Myriad Genetics Inc. (MYGN)
-NasdaqGS 31.43 
0.76(2.36%) May 24, 4:00PM EDT|After Hours
:
31.43 0.00 (0.00%) May 24, 4:05PM EDT
| Prev Close: | 32.19 |
|---|
| Open: | 31.81 |
|---|
| Bid: | N/A |
|---|
| Ask: | 33.41 x 500 |
|---|
| 1y Target Est: | 32.83 |
|---|
| Beta: | 1.05 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 31.02 - 32.02 |
|---|
| 52wk Range: | 22.02 - 34.70 |
|---|
| Volume: | 1,104,565 |
|---|
| Avg Vol (3m): | 1,178,060 |
|---|
| Market Cap: | 2.50B |
|---|
| P/E (ttm): | 20.04 |
|---|
| EPS (ttm): | 1.57 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Covidien's ENB Adopted by ACCPZacks(Thu, May 23)
- 6 Ways You Can Profit From Molecular Diagnosticsat Seeking Alpha(Wed, May 22)
- The Curious Case Of Human Gene Patentsat Forbes(Wed, May 22)
- Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosureat Motley Fool(Tue, May 21)
- QIAGEN Downgraded to Strong SellZacks(Tue, May 21)
- Charting a persistent May uptrendat MarketWatch(Tue, May 21)
- FDA Nod for COV's Advanced NellcorZacks(Tue, May 21)
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancerat Bloomberg(Mon, May 20)
- The Implications of Monsanto's Supreme Court Winat Motley Fool(Sun, May 19)
- Myriad Genetics: Disruptive Products For Cancer Diagnosticsat Seeking Alpha(Sun, May 19)
- CE Mark for STJ's ILUMIEN OPTISZacks(Fri, May 17)
- Stryker Reiterated at NeutralZacks(Fri, May 17)
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- Covidien Prices Senior NotesZacks(Thu, May 16)
- The Stock That May Have Saved Angelina Jolie's Life Could Get Another BoostStreetAuthority Network(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 16.99 |
|---|
| P/S (ttm): | 4.48 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | 1.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.35 |
|---|
Business Summary
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.
View More